This is a very informative discussion about the new indications of the  Cushing's Drug Isturisa® (osilodrostat) with Dr. Mario Maldonado, who heads global development for endocrinology at Recordati Rare Diseases.  The Food and Drug Administration recently approved the drug for endogenous hypercortisolism (excessive production of cortisol in the body).  If you want to learn more about this fascinating subject, Dr. Maldonado gives us an insider's view of how companies recognize and make decisions to pursue new indications, the intricacies of studying, analyzing, and understanding data, and the advantages that AI may bring to accelerate the development of new therapies. Our thanks to Dr. Maldonado and the Folks at Recordati for taking time from a busy conference to chat with us. You don't want to miss this talk!